The European Union approved CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass.
Rivaroxaban is a Factor Xa inhibitor and oral anticoagulant used to reduce blood clot formation in conditions such as atrial fibrillation, deep vein thrombosis and pulmonary embolism, and is approved to reduce the risk of major cardiovascular events in conditions such as coronary and peripheral artery disease.
CytoSorb is designed to reduce rivaroxaban during surgery to decrease pro-thrombotic risks and bleeding complications.
“CytoSorb can rapidly reduce rivaroxaban during a typical coronary artery bypass graft surgical procedure, so that waiting two-to-three days off the drug to allow the anticoagulant to be eliminated from the body is no longer necessary,” Vincent Capponi, CytoSorbent’s president and COO, said in a statement.
“We believe in time, CytoSorb has the potential to become a compelling and cost-effective standard of care for the removal of blood thinners during cardiac surgery,” he added.
